|
|
Worldwide Market for Rheumatoid Arthritis and Lupus Treatments ( Autoimmune Disease Markets )Published by: Kalorama Information Published: Jan. 1, 2008 - 180 Pages Table of Contents
Introduction Scope and Methodology Size and Growth of the Market Leading Competitors
History of the Market Immune System Autoimmunity Genetic Factors Environmental Factors Gene Research Distribution Technology Demographics
Overview Description of Rheumatoid Arthritis Diagnosis Treatment Guidelines Economic Impact of Disease Trends in Insurance and Reimbursement Description of products Non-steroid Anti-inflammatory Drugs Biologic Treatments Disease Modifying Anti-rheumatic Drugs (DMARDs) Immunosuppressant and Other Biologic Drugs New Developments Market Overview Market by Product Type Market by Geographical Region Competitive Analysis Corporate Profiles Abbott Laboratories Amgen, Inc Boehringer Ingelheim GmbH Bristol-Myers Squibb Centocor, Inc. Genentech, Inc. Merck & Company, Inc. Novartis International AG Pfizer, Inc. Schering-Plough Corporation Wyeth
Overview Description of Lupus Erythematosus Diagnosis Risk Factors Treatment Guidelines Economic Impact of Disease Trends in Insurance and Reimbursement Description of products New Developments Market Overview Market by Product Type Market by Geographical Region Competitive Analysis Corporate Profiles Aspreva Pharmaceuticals Corporation Bristol-Myers Squibb Genelabs Technologies, Inc. Genentech, Inc. GlaxoSmithKline plc Human Genome Sciences La Jolla Pharmaceutical Company Roche UCB S.A.
Overview Total Market Size and Forecast Markets by Segments Leading Competitors
CHAPTER ONE: EXECUTIVE SUMMARY Table 1-1: The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, 2004-2011 Figure 1-1: The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, 2004-2011
Figure 2-1: World Population by Selected Geographical Region, 2006-2050 Table 2-2: Estimated World Population by Age and Geographical Region, 2006 Table 2-2: Estimated World Population by Age and Geographical Region, 2006
Figure 3-1: World Prevalence of Rheumatoid Arthritis, Percent by Region Table 3-2: Select Marketed Non-steroidal Anti-inflammatory Drugs Table 3-3: Selected Prescription Disease Modifying Anti-Rheumatic Drugs Table 3-4: Selected Prescription Immunosuppressant and Other Biologic Drugs Table 3-5: New Developments in Rheumatoid Arthritis Figure 3-2: Number of New Developments for Rheumatoid Arthritis by Development Phase Table 3-6: The World Market for Prescription Rheumatoid Arthritis Treatments, 2004-2011 Figure 3-3: The World Market for Prescription Rheumatoid Arthritis Treatments, 2004-2011 Table 3-7: The World Market for Prescription Rheumatoid Arthritis Treatments, by Product Type, 2004-2011 Figure 3-4:The World Market for Prescription Rheumatoid Arthritis Treatments, by Product Type, 2004-2011 Figure 3-5: The World Market for Prescription Rheumatoid Arthritis Treatments, by Product Type and Percent Distribution, 2004-2011 Figure 3-6: The World Market for Prescription Rheumatoid Arthritis Treatments, by Percent and Product Type, 2006 Figure 3-7: The World Market for Prescription Rheumatoid Arthritis Treatments, by Percent and Product Type, 2011 Table 3-8: The World Market for Prescription Rheumatoid Arthritis, by Geographic Region, 2006 Figure 3-8: The World Market for Prescription Rheumatoid Arthritis, by Geographic Region, 2006 Table 3-9: Leading Suppliers’ Shares of the World Market for Prescription Rheumatoid Arthritis Treatments, 2006 Figure 3-9: Leading Suppliers’ Shares of the World Market for Prescription Rheumatoid Arthritis Treatments, 2006
Table 4-1: World Prevalence of Lupus by Region Figure 4-1: World Prevalence of Lupus, Percent by Region Table 4-2: Select Marketed Non-steroidal Anti-inflammatory Drugs Table 4-3: Selected Corticosteroids, Immunosuppressives and DMARDs Table 4-4: New Developments in Lupus Erythrematosus Figure 4-2: Number of New Developments for Lupus Erythrematosus by Development Phase Table 4-5: The World Market for Prescription Lupus Treatments, 2004-2011 Figure 4-3: The World Market for Prescription Lupus Treatments, 2004-2011 Table 4-6: The World Market for Prescription Lupus Treatments, by Product Type, 2004-2011 Figure 4-4: The World Market for Prescription Lupus Treatments, by Product Type, 2004-2011 Figure 4-5: The World Market for Prescription Lupus Treatments, by Product Type and Percent Distribution, 2004-2011 Figure 4-6:The World Market for Prescription Lupus Treatments, by Percent and Product Type, 2006 Figure 4-7:The World Market for Prescription Lupus Treatments, by Percent and Product Type, 2011 Table 4-7:The World Market for Prescription Lupus Treatments, by Geographic Region, 2006 Figure 4-8:The World Market for Prescription Lupus Treatments, by Geographic Region, 2006 Table 4-8:Estimated Leading Suppliers’ Shares of the World Market for Prescription Lupus Treatments, 2011 Figure 4-9:Estimated Leading Suppliers’ Shares of the World Market for Prescription Lupus Treatments, 2011
Table 5-1:The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, 2004-2011 Figure 5-1:The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, 2004-2011 Table 5-2:The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, by Product Type, 2004-2011 Figure 5-3:The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, by Product Type, 2004-2011 Figure 5-4:The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, by Product Type and Percent Distribution, 2004-2011 Figure 5-5:The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, by Percent and Product Type, 2006 Figure 5-6:The World Market for Prescription Rheumatoid Arthritis and Lupus Treatments, by Percent and Product Type, 2011 AbstractRheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United States, Europe and worldwide.
Kalorama's Worldwide Market for Rheumatoid Arthritis and Lupus Treatments (Autoimmune Disease Markets) is the most comprehensive look at the markets for treatments for these two important diseases in the autoimmune disorder category: rheumatoid arthritis and lupus. As part of its thorough, ground up research-- the product of interviews with market experts conducted by an experienced pharmaceutical market analyst, this report includes:
|
|
|||
|
About MarketResearch.com
|
||||